EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Combined Assessment of CTC and ESR1 Status in Liquid Biopsy Samples Enhances the Clinical Value of Prediction in Metastatic Breast Cancer

Malgorzata Szostakowska-Rodzos iD, Ewa A Grzybowska, Izabella Mysliwy iD, Renata Zub, Agnieszka Jagiello-Gruszfeld iD, Maryna Rubach, Aleksandra Konieczna, Anna Fabisiewicz iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26052038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Malgorzata Szostakowska-Rodzos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Polan…. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Breast Neoplasms, Estrogen Receptor alpha. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Maria Sklodowska-Curie National Research Institute of Oncology, Narodowe Centrum Nauki, Research Institute of Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monitoring of metastatic breast cancer (mBC) is an important issue in the clinical management of patients. Liquid biopsy has become a non-invasive method for detecting and monitoring cancer in body fluids. The presence of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in peripheral blood indicates poor prognosis and may contribute to early detection of progression, but assessment of these levels is still not routine clinical management. The main objective of this study was to estimate the frequency and clinical value of the ESR1 and PIK3CA mutations identified in circulating free DNA (cfDNA.) The second goal was to evaluate whether simultaneous evaluation of CTCs and mutation status in cfDNA increases the prognostic value of liquid biopsy. The results of the analysis of the CTC number and ESR1 and PIK3CA mutations in blood collected from 179 patients with metastatic breast cancer show that ESR1 mutations are more frequent in patients with advanced luminal breast cancer regardless of the type of the treatment. ESR1 mutations appear primarily during progression, as no mutations were found in primary tumor samples. The main conclusion of the study is that combined assessment of CTCs and ESR1 status in liquid biopsy may improve the prognostic value of liquid biopsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Cells, CirculatingBreast NeoplasmsEstrogen Receptor alphaHumansFemaleLiquid BiopsyMutationMiddle AgedClass I Phosphatidylinositol 3-KinasesCirculating Tumor DNAPrognosisAdultAgedBiomarkers, TumorNeoplasm Metastasis

Stichwörter der Autor:innen

ESR1 mutationPI3K mutationbreast cancercirculating tumor DNAcirculating tumor cellsdroplet digital PCRliquid biopsy

Substanzen

Estrogen Receptor alphaESR1 protein, humanClass I Phosphatidylinositol 3-KinasesCirculating Tumor DNAPIK3CA protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
  • Cancer Molecular and Genetic Diagnostics Department, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
  • Oncological Clinic, Oncological Mazovian Hospital, al. Solidarności 10, 03-411 Warsaw, Poland.
  • Cancer Chemotherapy Day Unit, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.
  • Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.

ORCID-Profile: Malgorzata Szostakowska-Rodzos, Izabella Mysliwy, Agnieszka Jagiello-Gruszfeld, Anna Fabisiewicz

Förderung

  • The Maria Sklodowska-Curie National Research Institute of Oncology
  • Narodowe Centrum Nauki
  • Research Institute of Oncology

Zitieren

APA

Szostakowska-Rodzos, M., Grzybowska, E. A., Mysliwy, I., Zub, R., Jagiello-Gruszfeld, A., Rubach, M., Konieczna, A., & Fabisiewicz, A. (2025). The Combined Assessment of CTC and ESR1 Status in Liquid Biopsy Samples Enhances the Clinical Value of Prediction in Metastatic Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26052038

Vancouver

Szostakowska-Rodzos M, Grzybowska EA, Mysliwy I, Zub R, Jagiello-Gruszfeld A, Rubach M, et al. The Combined Assessment of CTC and ESR1 Status in Liquid Biopsy Samples Enhances the Clinical Value of Prediction in Metastatic Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26052038

BibTeX
@article{SzostakowskaRodzos2025,
  author = {Szostakowska-Rodzos, Malgorzata and Grzybowska, Ewa A and Mysliwy, Izabella and Zub, Renata and Jagiello-Gruszfeld, Agnieszka and Rubach, Maryna and Konieczna, Aleksandra and Fabisiewicz, Anna},
  title = {The Combined Assessment of CTC and ESR1 Status in Liquid Biopsy Samples Enhances the Clinical Value of Prediction in Metastatic Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26052038}
}
Kostenlos starten →